4/A: Herbalife Executive Chairman Corrects SAR Exercise Price

Herbalife's Executive Chairman, Michael Johnson, filed an amended Form 4 to correct the exercise price of recently granted Stock Appreciation Rights.

Summary

• Michael Johnson, Executive Chairman of Herbalife Ltd., received a grant of 72,689 Restricted Stock Units (RSUs) and 399,619 Stock Appreciation Rights (SARs) on February 25, 2026.
• The RSUs and SARs were granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan.
• Both the RSUs and SARs will vest in two equal installments: 50% on February 25, 2027, and the remaining 50% on February 25, 2028, contingent on continued service.
• An amendment to the original Form 4 was filed solely to correct the exercise price of the SARs from the previously reported $10.51 to the correct price of $19.26.
• Following these transactions, Michael Johnson beneficially owns 887,415 shares of Common Stock and 399,619 Stock Appreciation Rights.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative procedural update. While the grants themselves are positive for executive alignment, the correction of the SAR exercise price to a higher value makes the terms less favorable for the executive, which could be perceived negatively by some.

Positives

• Grant of 72,689 Restricted Stock Units (RSUs) and 399,619 Stock Appreciation Rights (SARs) aligns executive compensation with long-term shareholder value.
• The vesting schedule over two years (50% on February 25, 2027, and 50% on February 25, 2028) incentivizes continued service and performance.

Negatives

• The correction of the SAR exercise price from $10.51 to $19.26 indicates a higher hurdle for the SARs to become in-the-money, potentially reducing their intrinsic value at the time of grant compared to the initially reported figure.
• The grants are subject to continued service, meaning the executive must remain with the company to realize the full benefit.

Risks

• The value of the RSUs and SARs is subject to the future performance of Herbalife's common stock.
• The SARs' value is dependent on the stock price exceeding the corrected exercise price of $19.26.

Future Outlook

The grants of RSUs and SARs are tied to future performance and continued service, with vesting scheduled for February 25, 2027, and February 25, 2028. The SARs have an expiration date of February 25, 2036.

Industry Context

StockSavvy.ai notes that executive compensation packages often include equity awards like RSUs and SARs to align management's interests with long-term shareholder value. The use of SARs, which provide value based on stock price appreciation without requiring an upfront investment from the executive, is a common practice in the consumer health and direct selling industries, similar to peers like Nu Skin Enterprises or USANA Health Sciences.

Comparison to Industry Standards

• The grant of equity awards to executive leadership, such as RSUs and SARs, is a standard practice across publicly traded companies, including those in the health and wellness sector like Herbalife.
• Vesting schedules over multiple years, like the two-year schedule for these grants, are typical for long-term incentive plans, comparable to practices at companies such as GNC Holdings or Vitamin Shoppe, which aim to retain key executives and incentivize sustained performance.
• The correction of an exercise price, while not ideal, is a procedural amendment that can occur in complex equity compensation reporting, and similar amendments are occasionally seen in filings from other large corporations.

Stakeholder Impact

• Shareholders: The grants align executive interests with shareholder value creation, but the higher SAR exercise price means the stock needs to perform better for the executive to benefit, potentially indicating a more challenging path to executive payout.

Next Steps

• First tranche of RSUs and SARs will vest on February 25, 2027.
• Second tranche of RSUs and SARs will vest on February 25, 2028.
• The Stock Appreciation Rights will expire on February 25, 2036.

Key Dates

Recommendation

This filing is an amendment to an insider transaction report, primarily correcting an exercise price for executive equity awards. It does not contain new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The correction itself makes the awards slightly less favorable for the executive, but this is a minor detail in the broader investment thesis for Herbalife. Therefore, a "hold" recommendation remains appropriate, pending more substantive operational or financial updates.

Keywords

Herbalife, HLF, Form 4/A, SEC Filing, Michael Johnson, Executive Compensation, Restricted Stock Units, RSUs, Stock Appreciation Rights, SARs, Beneficial Ownership, Corporate Governance